Parkwalk has led a $2.5m investment round into Echopoint Medical, a UCL spinout, which has developed core photonic sensor technology to greatly enhance the diagnosis and treatment of coronary heart disease.
The funding will support Echopoint as it advances towards FDA submission and launches its US clinical programme, generating real-world evidence for its technology.
Echopoint’s mission is to make comprehensive coronary physiology assessment more practical and consistent in clinical settings. Its iKOr™ platform is designed to provide a rapid, in-depth assessment of coronary physiology, including critical aspects of the microvasculature that are often overlooked, all within seconds.
The investment will enable the company to accelerate its clinical and regulatory progress as it prepares for commercialisation in the US market.
To find out more about Echopoint, visit their website or our portfolio page here.